SCHEMBL7124349

SCHEMBL7124349

Fc1ccc(SCCCN2CCN(c3cccc4ccsc34)CC2)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 12/20 0.46
HTR1A P08908 12/20 0.46
HTR2A P28223 8/20 0.46
DRD3 P35462 7/20 0.41
DRD1 P21728 2/20 0.41
DRD5 P21918 2/20 0.41
GRM2 Q14416 1/20 0.38
HTR2C P28335 2/20 0.38
HRH1 P35367 1/20 0.38
KCNH2 Q12809 2/20 0.37
PARP1 P09874 1/20 0.37
PARP2 Q9UGN5 1/20 0.37
DRD4 P21917 2/20 0.37
ADRA1D P25100 2/20 0.37
ADRA1A P35348 2/20 0.37
ADRA1B P35368 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7124989 0.97 DRD2 (0.48) DRD2HTR1AHTR2ADRD3DRD1
SCHEMBL7129868 0.87 DRD2 (0.50) DRD2HTR1AHTR2ADRD3GRM2
SCHEMBL7119363 0.83 DRD2 (0.52) DRD2HTR1AHTR2ADRD3DRD5
SCHEMBL7119957 0.81 DRD2 (0.50) DRD2HTR1AHTR2ADRD3KCNH2
SCHEMBL7126246 0.80 DRD2 (0.53) DRD2HTR1AHTR2ADRD3KCNH2
SCHEMBL7117583 0.79 DRD2 (0.55) DRD2HTR1AHTR2ADRD3KCNH2
SCHEMBL7120269 0.79 HTR1A (0.56) DRD2HTR1ADRD4ADRA1A
SCHEMBL7120429 0.78 DRD2 (0.52) DRD2HTR1AHTR2ADRD3KCNH2
SCHEMBL7127109 0.77 DRD2 (0.47) DRD2HTR1AHTR2ADRD3DRD1
SCHEMBL7093710 0.77 GAA (0.51) DRD2HTR1ADRD3KCNH2DRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US claimed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP claimed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO claimed
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use H. LUNDBECK A/S (DK) 2003-03-13 US disclosed
EP-1246820-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2002-10-09 EP disclosed
WO-2001049683-A1 NOVEL HETEROARYL DERIVATIVES, THEIR PREPARATION AND USE H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030050306-A1 Novel heteroaryl derivatives, their preparation and use CRBN, CDR2, DRD3 DRD2 7/4885HTR1A 74/4885HTR2A 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.